Search form

Advanced Search
 
Thursday June 30, 2016

Rutgers Scientists Find New Benefit to Lou Gehrig's Drug in Treating Melanoma

Wednesday January 21, 2015

Rutgers Scientists Find New Benefit to Lou Gehrig's Drug in Treating Melanoma

Your Source for University News
Media Contact:
Michele Fisher
732-235-9872

A drug used to treat Lou Gehrig's disease (ALS) makes radiation more effective when treating melanoma that has metastasized to the brain, according to new research on laboratory models at Rutgers Cancer Institute of New Jersey and the Ernest Mario School of Pharmacy at Rutgers.

Melanoma – the deadliest of skin cancers – is often resistant to radiation therapy, creating a risk of neurotoxicity when large doses need to be administered to the whole brain in order to treat the disease. The new study, published in the current print edition of Pigment Cell & Melanoma Research (doi: 10.1111pcmr.12327), examines radiation treatment when combined with the drug riluzole and its impact on melanoma that has spread to the brain.

Suzie Chen
Suzie Chen
Riluzole targets a protein known as GRM1 that is often abnormally produced by melanoma cells and increases growth and spread of the disease. Riluzole has been approved by the United States Food and Drug Administration and is being used to to block activation of the GRM1 protein in the treatment of ALS, a disease that affects nerve cells in the brain and spinal cord.

In the new Rutgers research, investigators found that treating the melanoma daily, over a 37 day period, with riluzole and a weekly dose of radiation, led to a decrease in tumor cell growth.

“What this indicates is that riluzole sensitizes GRM1, helping these proteins act like a beacon for radiation so that only melanoma cells with the GRM1 protein will be targeted, sparing the rest of the brain and preserving the brain’s functionality,” notes senior author, Suzie Chen, Cancer Institute member and professor of chemical biology at the Ernest Mario School of Pharmacy.

James S. Goydos
James S. Goydos
“With approximately 50 percent of patients with melanoma developing brain metastasis and fewer than 13 percent of those patients surviving one year or more, identifying new therapies for this population is paramount,” says James S. Goydos, director of the Melanoma and Soft Tissue Oncology Program at the Cancer Institute and professor of surgery at Rutgers Robert Wood Johnson Medical School, who is another author on the study. He also notes their findings could have even broader implications. “Because the GRM1 protein is also found in breast and prostate cancers, pre-treatment with riluzole before radiation for these particular cancers might also result in the same outcomes,” he said.

Along with Drs. Chen and Goydos, the author team consists of Brian A. Wall and Lumeng J. Yu, both School of Pharmacy; and Atif Khan and Bruce Haffty, both Cancer Institute.

Media Contact:
Michele Fisher
732-235-9872
Your Source for University News